Tag Archives: Ed Kissel

In the Absence of Avastin: New Opportunity

written by guest blogger Ed Kissel, Vice President of Quantitative Analysis In July 2010, an advisory panel voted 12-1 to urge the FDA to withdraw the approved use of Avastin in metastatic HER2-negative breast cancer. As a result of this announcement, IntrinsiQ hypothesized that physicians would immediately decrease the use the drug in new patients. […]
Posted in Strategy | Also tagged | Leave a comment
  • Categories

  • Meta